{"adverse_reactions":["ADVERSE REACTIONS SECTION Prolonged use may produce local irritation, characterized by follicular conjunctivitis, vascular congestion, edema, exudate, and an eczematoid dermatitis. Somnolence, dryness of the mouth, or visual hallucinations may occur."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY SECTION This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia)."],"contraindications":["CONTRAINDICATIONS SECTION Contraindicated in persons with primary glaucoma or a tendency toward glaucoma, e.g., narrow anterior chamber angle; and in those showing hypersensitivity to any component of this preparation."],"description":["DESCRIPTION SECTION ISOPTO® Hyoscine (scopolamine hydrobromide ophthalmic solution) is an anticholinergic prepared as a sterile topical ophthalmic solution. The active ingredient is represented by the chemical structure: Established name: scopolamine hydrobromide Chemical name: benzeneacetic acid, α-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo[3.3.1.0 2,4 ]non-7-yl ester, hydrobromide, trihydrate, [7( S )-(1α,2β,4β,5α,7β)]-. Each mL contains: Active: scopolamine hydrobromide 0.25%. Preservative: benzalkonium chloride 0.01%. Vehicle: hypromellose 0.5%. Inactives: sodium chloride, glacial acetic acid, sodium acetate (to adjust pH), purified water."],"dosage_and_administration":["DOSAGE & ADMINISTRATION SECTION For refraction, administer one or two drops in the eye(s) one hour before refracting. For uveitis, administer one or two drops in the eye(s) up to four times daily."],"effective_time":"20070601","how_supplied":["HOW SUPPLIED SECTION In 5 mL plastic DROP-TAINER® dispensers. 5 mL NDC 0998-0331-05"],"id":"2a5458a9-484b-e264-2c20-2407d4f540f8","indications_and_usage":["INDICATIONS & USAGE SECTION For mydriasis and cycloplegia in diagnostic procedures. For some pre- and postoperative states when a mydriatic and cycloplegic is needed in treatment of iridocyclitis."],"openfda":{},"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 0998-0331-05 Alcon ® Isopto ® Hyoscine 0.25% (scopolamine hydrobromide ophthalmic solution) 5 mL Sterile"],"precautions":["PRECAUTIONS SECTION To avoid excessive absorption, the lacrimal sac should be compressed by digital pressure for two to three minutes after instillation. To avoid inducing angle closure glaucoma, an estimation of the depth of the angle of the anterior chamber should be made. Patient Warning Patient should be advised not to drive or engage in other hazardous activities when drowsy or while pupils are dilated. Patient may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child’s mouth and to wash their own hands and the child’s hands following administration. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"set_id":"d7013892-0a00-afd3-cc62-99c195f48c7a","spl_product_data_elements":["Isopto Hyoscine scopolamine hydrobromide Scopolamine Hydrobromide Scopolamine Benzalkonium Chloride Hypromelloses Sodium Chloride Acetic Acid Sodium Acetate Water Chemical Diagram Carton Label"],"storage_and_handling":["STORAGE SECTION Store at 8°-27°C (46°-80°F). Protect from light. Rx Only Revised: June 2007 9002667-0607 ALCON LABORATORIES, INC. Ft. Worth, Texas 76134 USA Printed in USA © 2003, 2007 Alcon, Inc."],"version":"2","warnings":["WARNINGS SECTION Do not touch dropper tip to any surface, as this may contaminate the solution. FOR TOPICAL OPHTHALMIC USE ONLY - NOT FOR INJECTION."]}